| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| Targets |
Androgen Receptor (AR) DNA-binding domain (AR-DBD).
|
|---|---|
| ln Vitro |
In LNCaP, C4-2, MR49F, and 22Rv1 cells, VPC-14449 (0.01-100 μM; 24 hours) suppresses AR transcriptional activity and cell viability [2]. Without altering the expression of AR protein, VPC-14449 (0.01-100 μM; 24 h) dose-modeled suppression of transiently produced full-length human AR in PC3 cells (IC50=0.34 μM) [1].
VPC-14449 reduces the ability of full-length AR as well as AR variants to interact with chromatin, thereby blocking AR-mediated transcriptional activation. It inhibits AR activity without affecting AR protein expression. |
| ln Vivo |
VPC-14449 (100 mg/kg; intraperitoneally injected twice daily for 4 weeks) decreased tumor volume and stopped PSA production in the LNCaP xenograft model [1]. The animals were weighed at the end of the 4 week treatment.
No detailed in vivo activity data is available for this compound. As an AR-DBD inhibitor, VPC-14449 is expected to exhibit antitumor efficacy in prostate cancer models by inhibiting AR-driven gene expression, but specific in vivo studies have not been reported. |
| Enzyme Assay |
The compound is evaluated in cell-free binding assays to assess its ability to disrupt AR-DBD interaction with DNA. These assays typically use recombinant AR-DBD protein and fluorescently labeled DNA probes in fluorescence polarization or electrophoretic mobility shift assays to measure the inhibition of AR-DNA complex formation.
|
| Cell Assay |
Cell Viability Assay [2]
Cell Types: LNCaP, C4-2, MR49F and 22Rv1 Cell Tested Concentrations: 0.01, 0.1, 10, 100 μM Incubation Duration: 24 hrs (hours) Experimental Results: Inhibition of growth of each cell line tested. Western Blot Analysis[2] Cell Types: LNCaP, C4-2, MR49F and 22Rv1 Cell Tested Concentrations: 0.01, 0.1, 10, 100 μM Incubation Duration: 24 hrs (hours) Experimental Results: Inhibition of endogenous in LNCaP, C4-2 and MR49F cells AR transactivation is stimulated by the synthetic androgen R1881. VPC-14449 is tested in cell-based luciferase reporter assays using prostate cancer cell lines transfected with full-length human AR constructs. The compound shows an IC50 of 0.34 μM for inhibiting full-length AR transcriptional activity, with its effect on AR variants also being evaluated in similar reporter systems. |
| Animal Protocol |
Animal/Disease Models: Nude mice (Harlan SD (SD (Sprague-Dawley)); 25-31 g; 6-8 weeks) were inoculated subcutaneously (sc) (sc) with LNCaP cells and castrated [1]
Doses: 100 mg/kg Route of Administration: intraperitoneally (ip) (ip) twice (two times) daily for 4 weeks Experimental Results: Inhibits LNCaP tumor volume and prevents serum PSA production. No detailed in vivo animal experimental protocol is available for this compound. For AR inhibitors, typical in vivo studies involve subcutaneous xenograft models using AR-positive prostate cancer cells in immunodeficient mice, with compound administered via oral or intraperitoneal routes to assess tumor growth inhibition. |
| ADME/Pharmacokinetics |
No detailed pharmacokinetic data is available for VPC-14449. With a molecular weight of 394.09, the compound is expected to have suitable drug-like properties, but specific PK parameters such as bioavailability, half-life, and plasma protein binding have not been reported.
|
| Toxicity/Toxicokinetics |
No detailed toxicological data is available for this compound. As a research-grade chemical probe, standard preclinical toxicity assessments have not been published, and the compound is intended for in vitro and preclinical research use only.
|
| References |
|
| Additional Infomation |
VPC-14449 has a molecular formula of C10H10Br2N4OS and a molecular weight of 394.09. It is being investigated for the research of prostate cancer, particularly for targeting AR splice variants that drive castration-resistant prostate cancer. The compound has not entered clinical trials and is not FDA-approved for therapeutic use.
|
| Molecular Formula |
C10H10BR2N4OS
|
|---|---|
| Molecular Weight |
394.08
|
| Exact Mass |
391.894
|
| CAS # |
1621375-32-3
|
| Related CAS # |
1621375-32-3;2230880-25-6 (45-dibromo-isomer);
|
| PubChem CID |
135150480
|
| Appearance |
White to off-white solid powder
|
| Density |
2.1±0.1 g/cm3
|
| Boiling Point |
542.8±60.0 °C at 760 mmHg
|
| Flash Point |
282.1±32.9 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.802
|
| LogP |
0.93
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
18
|
| Complexity |
295
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1COCCN1C2=NC(=CS2)N3C=C(N=C3Br)Br
|
| InChi Key |
AZLNRGRZOLVWRX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H10Br2N4OS/c11-7-5-16(9(12)13-7)8-6-18-10(14-8)15-1-3-17-4-2-15/h5-6H,1-4H2
|
| Chemical Name |
4-[4-(2,4-dibromoimidazol-1-yl)-1,3-thiazol-2-yl]morpholine
|
| Synonyms |
VPC14449; VPC 14449; VPC-14449
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~317.19 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.28 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.28 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (5.28 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5376 mL | 12.6878 mL | 25.3756 mL | |
| 5 mM | 0.5075 mL | 2.5376 mL | 5.0751 mL | |
| 10 mM | 0.2538 mL | 1.2688 mL | 2.5376 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
